99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

慢性HBV感染者血清IGF-1和IGFBP-3水平及其临床意义

目的 通过检测慢性HBV感染者血清IGF-1和IGFBP-3水平,探讨其对于慢性HBV感染分期诊断的临床意义及应用价值.方法 采用化学发光免疫分析法检测各组研究对象血清IGF-1和IGFBP-3水平.分析血清IGF-1和IGFBP-3水平在不同组别间的统计学差异及其与ALT等常用肝功能及肝损伤指标的相关性,并评价其在HBV感染相关炎症中的诊断效能.结果 与健康对照组相比,慢性HBV感染患者的血清IGF-1和IGFBP-3水平低于健康对照组,差异有统计学意义(P均<0.05);运用ROC曲线对慢性HBV感染引起的肝脏炎症中ALT、IGF-1和IGFBP-3诊断效能进行计算、比较,结果显示3者的ROC曲线下面积(AUC)分别为0.933、0.611、0.743,其中ALT的灵敏度,特异性均高于IGF-1和IGFBP-3,但IGF-1和IGFBP-3均有预测价值(AUC>0.5),且3者联合检测时AUC可提高至0.946.结论 IGF-1和IGFBP-3对于HBV感染引起的肝脏炎症有预测价值,虽然不能比ALT更好地反映HBV感染引起的肝脏炎症,但是ALT、IGF-1和IGFBP-3联合检测可提高诊断效能.     

2017-01目录

目的 研究99Tcm-联肼尼克酰胺-3聚乙二醇-精氨酸-甘氨酸-天冬氨酸环肽二聚体（99Tcm-3PRGD2）整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比。方法 选取初诊乳腺占位患者84例,均为女性。所有患者行2 h、4 h 99Tcm-3PRGD2 整合素受体显像及钼靶检查,以术后病理结果作为“金标准”,比较不同显像方法（全身显像及胸部SPECT/CT显像）对乳腺癌定性诊断的价值,并与钼靶结果进行对比分析。采用SPSS22.0软件,对数据进行t检验和χ2检验。结果 SPECT/CT显像的诊断效能高于全身显像;乳腺癌99Tcm-3PRGD2摄取率[病灶容积最大计数（T_max）、病灶容积平均计数（T_mean）、T_max/本底平均计数（B）值及T_mean/B值]均明显高于良性占位（t=2.09~3.19,均P＜0.05）,且T_max/B值差异更为明显（t=3.19,P＜0.01）;2 h、4 h显像对乳腺癌诊断效能差异无统计学意义（t=0.63~1.25,均P>0.05）。SPECT/CT显像诊断乳腺癌的灵敏度大于95.0%,联用钼靶后灵敏度可以提高到98.4%;对致密型乳腺患者,SPECT/CT显像与钼靶诊断乳腺癌的灵敏度、特异度、准确率分别为95.2%、83.3%、91.7%和78.6%、76.2%、77.8%,前者的准确率高于后者,且差异有统计学意义（χ2=4.341,P＜0.05）。结论 99Tcm-3PRGD2 SPECT/CT显像定性诊断乳腺癌具有高灵敏度,是对钼靶的有益补充,尤其对致密型乳腺占位患者具有独特优势。     

血清肿瘤标志物CEA、CYFRA21-1、CA50、CA19-9、CA125联合检测对肺癌的诊断价值探讨

目的　探讨肿瘤标志物 CEA、CYFRA2 1- 1、CA5 0、CA19- 9、CA12 5辅助诊断肺癌的临床应用价值。方法　采集 16 0例住院患者的血清 ,其中肺癌 131例 ,肺部良性病变 (BL D) 2 9例 ,用化学发光法检测其血清癌胚抗原 (CEA)、糖链抗原 (CA19- 9)、糖链抗原 (CA12 5 ) ,用免疫放射法检测血清糖链抗原 (CA5 0 )、细胞角质蛋白19(CYFRA2 1- 1)的含量。结果　肺癌组患者血清 CEA、CYFRA2 1- 1、CA5 0、CA19- 9、CA12 5含量明显高于 BL D(P<0 .0 0 1) ;CEA+CYFRA2 1- 1+CA19- 9、 CEA+CYFRA2 1- 1+CA5 0和 CEA+CYFRA2 1- 1+CA12 5联合检测肺癌敏感性较单项检测提高 ,分别为 71.6 %、 79.1%、 83.7% ;CEA、 CA5 0、 CA12 5、 CA19- 9、 CYFRA2 1- 1的含量随肺癌病情进展和分期而升高。结论　肺癌患者血清 CEA、CYFRA2 1- 1、CA5 0、CA19- 9、CA12 5含量明显高于 BL D。血清肿瘤标志物联合检测可提高诊断肺癌敏感性。     

腮腺核素显像半定量分析与干燥综合征患者唇腺病理检查分级的关系

目的探讨腮腺核素显像半定量分析与干燥综合征（SS）患者唇腺病理检查分级的相关性,以评价其在SS早期诊断和病情判断中的价值。方法对135例SS患者及30名健康志愿者（对照组）行常规腮腺核素显像和半定量分析,计算半定量指标：腮腺最大浓聚率（MAR）、腮腺酸刺激后最大分泌率（MSR）、酸刺激后腮腺达到最低放射性计数所需的时间（t腮腺）、酸刺激前口内活性指数（PRI）、酸刺激后口内活性指数（POI）。所有患者在显像检查后均获得唇腺病理检查结果,根据病理变化分为：0,1,2,3,4级。将各病理分级组的半定量指标与对照组进行比较（单因素方差分析和q检验）,并且与唇腺病理分级结果进行相关性分析。结果病理分级3级以上组与对照组比较,所有半定量指标差异均有统计学意义（q=6．79～38．64,P均〈0．01）;而病理1～2级组与对照组的比较,仅PRI和POI差异有统计学意义（q值分别为8．33和8．63,P均〈0．01）。MAR和MSR均随病理分级增加而减少,与病理分级呈负相关（r值分别为-0．679和-0．601,P均〈0．01）。t腮腺随病理分级增加而延长,与病理分级呈正相关（r=0．364,P〈0．01）。PRI和POI也随病理分级增加而明显减低,与病理分级呈负相关（r值分别为-0．724和-0．751,P〈0．01）。结论腮腺核素显像有关半定量指标与SS唇腺病理改变分级有相关性,提示其可用于评价SS的病变程度和监测病情变化,而口腔相关指标对SS的早期诊断可能更有价值。     

99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

99Tcm-Octreotide显像在甲状腺实性“冷结节”定性诊断中的价值

流行病学调查显示,超声发现甲状腺结节阳性率达19％ ～ 67％[1],对甲状腺结节进行早期定性诊断是临床亟需解决的问题.99Tcm-Octreotide作为新型SSTR显像剂,可在甲状腺恶性结节中呈高摄取[2].本研究筛选50例甲状腺实性"冷结节"患者进行SSTR显像,以评价其定性诊断恶性甲状腺结节的效能,现报道如下.     

99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

血浆脑利钠肽在快速鉴别诊断心源性和肺源性呼吸困难中的价值

目的 评价血浆脑利钠肽(BNP)水平在心源性和肺源性呼吸困难时鉴别诊断的价值.方法 采用美国拜尔公司生产的化学发光检测仪及其BNP试剂,检测248例因呼吸困难住院的肺疾病患者血浆BNP水平,对单纯肺疾病患者、肺疾病并发左心功能不全患者、肺疾病未并发左心功能不伞患者、肺疾病并发右心衰患者各组间BNP水平进行比较.结果 肺疾病并发左心功能不全的呼吸困难患者的BNP水平明显高于未并发左心功能不全的呼吸困难患者(x2=25.597,P<0.001);肺疾病并发右心衰患者BNP水平高于单纯肺疾病患者,但差异没有统计学意义(t=1.614,P0.05);肺疾病并发左心功能不全患者的BNP水平明显高于肺疾病并发右心衰患者(t=2.531,P<0.05);肺疾病并发左心功能不全患者的心功能越差,BNP水平就越高,心功能Ⅱ、Ⅲ、Ⅳ级三组间BNP水平的差别有统计学意义(x2=29.463,P<0.001).结论 血浆BNP是快速鉴别诊断心源性和肺源性呼吸困难的重要实验窜检测指标,同时可判断肺疾病并发左心功能不全患者心衰的严重程度.     

腮腺动态显像评价鼻咽癌放疗对腮腺功能的影响

目的 探讨腮腺动态显像评价鼻咽癌放疗对腮腺功能影响的价值。方法 21例鼻咽癌患者分别于放疗前、后行放射性核素腮腺动态显像,计算腮腺摄取指数(UI)、酸刺激后的分泌率(ER)、分泌指数(EI)等半定量指标以评价放疗前后腮腺功能的变化。结果 放疗后与放疔前比较,所有患者UI、ER、EI均显著下降,t值分别为56.65、41.34、30.69,P<0.001,腮腺摄取与分泌功能均明显受损,与患者临床口干症状相符。结论 腮腺动态显像是一种评价鼻咽癌放疗对腮腺功能的影响的有用方法,具有临床应用价值。